Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
115 hedge funds and large institutions have $211M invested in Accelerate Diagnostics in 2020 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 41 increasing their positions, 24 reducing their positions, and 13 closing their positions.
71% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 24
31% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 13
3% more funds holding
Funds holding: 112 → 115 (+3)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
32% less capital invested
Capital invested by funds: $311M → $211M (-$100M)
91% less call options, than puts
Call options by funds: $185K | Put options by funds: $2.15M
Top Buyers
| 1 |
LA
Linden Advisors
New York
|
+$2.32M |
| 2 |
Two Sigma Investments
New York
|
+$1.55M |
| 3 |
D.E. Shaw & Co
New York
|
+$1.24M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$1.02M |
| 5 |
Renaissance Technologies
New York
|
+$973K |
Top Sellers
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$7.3M |
| 2 |
AG
Artal Group
Luxembourg
|
-$4.56M |
| 3 |
CC
Chicago Capital
Chicago,
Illinois
|
-$3.21M |
| 4 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$2.56M |
| 5 |
William Blair & Company
Chicago,
Illinois
|
-$2.21M |
AXDX Hedge Fund Activity: Q4 2020 in Review
115 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q4 2020, worth a combined $211M — down 32% from $311M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new AXDX positions and 13 closed out — a net gain of 4 holders — while 41 added to existing stakes and 24 trimmed.
The largest buyer was Linden Advisors, opening a new position worth an estimated $2.32M. The largest seller was ArrowMark Colorado Holdings, exiting entirely with an estimated $7.3M sold.
- 115 institutional investors held Accelerate Diagnostics (AXDX) as of Q4 2020, up from 112 in Q3 2020.
- Funds reported $211M of Accelerate Diagnostics stock for Q4 2020, down 32% quarter-over-quarter.
- 17 funds opened new Accelerate Diagnostics positions in Q4 2020 and 13 closed out, a net change of +4 holders.
- The largest Accelerate Diagnostics buyer in Q4 2020 was Linden Advisors, an estimated $2.32M added.
- The largest Accelerate Diagnostics seller in Q4 2020 was ArrowMark Colorado Holdings, an estimated $7.3M sold.
Based on aggregated 13F filings for Q4 2020.